<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03945955</url>
  </required_header>
  <id_info>
    <org_study_id>H19-00780</org_study_id>
    <nct_id>NCT03945955</nct_id>
  </id_info>
  <brief_title>Melatonin and DNA Damage Study</brief_title>
  <official_title>Melatonin, Nightshift Work and DNA Damage (MEND) Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of British Columbia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research aims to determine if melatonin supplementation, through improvements in sleep
      quality, increases the ability to repair oxidative DNA damage and reduce lipid peroxidation
      levels among nightshift workers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Administering a 3 mg melatonin supplement to nightshift workers prior to day sleep may
      significantly improve their oxidative DNA damage repair capacity and reduce the occurrence of
      lipid peroxidation [measured as increased excretion of urinary 8-hydroxydeoxyguanosine
      (8-OH-dG) and decreased excretion of urinary 8-isoprostane, respectively] through
      improvements in sleep quality (measured via actigraphy) and melatonin's direct antioxidative
      properties.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2019</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline oxidative DNA damage repair capacity at one month</measure>
    <time_frame>During day sleep and during night work at baseline and one month</time_frame>
    <description>Measured as difference in the urinary concentration of 8-hydroxydeoxyguanosine (ng/mg-Creatinine) between baseline and one month as measured using liquid chromatography tandem mass spectrometry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline lipid peroxidation at one month</measure>
    <time_frame>During day sleep and during night work at baseline and one month</time_frame>
    <description>Measured as difference in the concentration of urinary 8-isoprostane (ng/mg-Creatinine) between baseline and one month using liquid chromatography tandem mass spectrometry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in sleep duration at one month</measure>
    <time_frame>During day sleep at baseline and one month</time_frame>
    <description>Measured as difference in sleep duration (total minutes asleep) using wrist-based actigraphy device between baseline and one month</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Sleep Quality</condition>
  <condition>DNA Damage Repair Deficiency</condition>
  <condition>Oxidative Stress</condition>
  <arm_group>
    <arm_group_label>Melatonin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Melatonin</intervention_name>
    <description>Participants will be randomized into two groups (Group A and Group B). Group A will initially be treated with 3 mg melatonin supplements over a 4-week period while Group B will initially receive placebo supplements over a 4-week period. After a 4-week washout period, Group A will receive placebo supplements while Group B will receive 3 mg melatonin supplements.</description>
    <arm_group_label>Melatonin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 18-40 years of age;

          2. Live in Vancouver, Burnaby, New Westminster or Richmond;

          3. Primarily work nightshifts of 7 or more hours in duration that end no earlier than 6
             am at least 3 nights per week over the past 6 months or more;

          4. Sleep at least 6 hours each day after completing a night shift

        Exclusion Criteria:

          1. Currently using any tobacco or marijuana products or illicit drugs;

          2. Typically drink more than two alcoholic beverages on a work day;

          3. Have personal history of hypertension, hypercholesterolemia, low blood sugar,
             migraines, hormonal disorders, seizures disorders, depression or chronic medical
             condition (e.g. cancer, diabetes, kidney disease, liver disease, asthma,
             cardiovascular disease, infectious disease etc.)

          4. Currently pregnant;

          5. Currently breast feeding;

          6. Have traveled across more than one time zone in the past 4 weeks or are planning to
             travel across more than one time zone during participation in the study;

          7. Have been diagnosed or are suspected to have circadian or sleep disorders (e.g sleep
             apnea, narcolepsy);

          8. Currently using melatonin supplements.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Parveen Bhatti, PhD</last_name>
    <phone>604-675-8055</phone>
    <email>pbhatti@bccrc.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maryam Darvishian, PhD</last_name>
    <phone>604-675-8070</phone>
    <email>mdarvishian@bccrc.ca</email>
  </overall_contact_backup>
  <results_reference>
    <citation>Bhatti P, Mirick DK, Randolph TW, Gong J, Buchanan DT, Zhang JJ, Davis S. Oxidative DNA damage during night shift work. Occup Environ Med. 2017 Sep;74(9):680-683. doi: 10.1136/oemed-2017-104414. Epub 2017 Jun 26.</citation>
    <PMID>28652381</PMID>
  </results_reference>
  <results_reference>
    <citation>Mirick DK, Bhatti P, Chen C, Nordt F, Stanczyk FZ, Davis S. Night shift work and levels of 6-sulfatoxymelatonin and cortisol in men. Cancer Epidemiol Biomarkers Prev. 2013 Jun;22(6):1079-87. doi: 10.1158/1055-9965.EPI-12-1377. Epub 2013 Apr 5.</citation>
    <PMID>23563887</PMID>
  </results_reference>
  <results_reference>
    <citation>Bhatti P, Mirick DK, Davis S. The impact of chronotype on melatonin levels among shift workers. Occup Environ Med. 2014 Mar;71(3):195-200. doi: 10.1136/oemed-2013-101730. Epub 2014 Jan 7.</citation>
    <PMID>24399070</PMID>
  </results_reference>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>April 30, 2019</study_first_submitted>
  <study_first_submitted_qc>May 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 10, 2019</study_first_posted>
  <last_update_submitted>May 8, 2019</last_update_submitted>
  <last_update_submitted_qc>May 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of British Columbia</investigator_affiliation>
    <investigator_full_name>Parveen Bhatti</investigator_full_name>
    <investigator_title>Scientific Director, Cancer Prevention, BC Cancer Research Centre</investigator_title>
  </responsible_party>
  <keyword>Melatonin, Sleep quality, DNA Damage, Lipid peroxidation, Nightshift worker</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melatonin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

